Interaction between Codon 49 genotype and treatment
The analysis results of Codon 49 genotype was shown in figure 1A . As shown in 19 Table 1 and 2, there was no significant difference in baseline characteristics, 20 echocardiographic data and pharmacotherapy during 1-year follow-up period 21 (P>0.05). Compared with the G-allele carriers, a homozygote tended to obtain better 22 systolic function recovery and more left ventricular size reduction according to 23 echocardiography within 12-months follow-up; however, they were not statistically 24 different (Figure 2 and Table 3 and 4). 1-year MACE incidence among patients with 25 AA genotype was13.7%; whereas, it was 21.4% among G-allele carriers (P = 0.208). 27 The analysis results of Codon 389 genotype was shown in figure 1B. There were no 28 significant difference between different genotypes of Codon 389 in baseline 29 characteristics, echocardiography and pharmacotherapy (P>0.05, Table 5 and 6).
Interaction between Codon 389 genotype and treatment
During the whole study, patients carrying G homozygous gene tended to have better 1 EF and left ventricular size improvement compared with C-allele carriers ( Figure   2 3A,3B,3C and Table 7 ). In further analysis shown in Table 8 , Figure 3D ,3E and 3F, 3 patients with GG genotype responded better to pharmacotherapy, especially when 4 comparing with those with CC genotype, as shown in EF increase (P = 0.000), LVDd 5 reduction (P = 0.007) and LVDs reduction (P = 0.001), at 12-month time point.
6
Towards the end of the study, similar favorable responses among CG genotype were 7 observed comparing with CC genotype, as shown in EF increase (P= 0.019) and 8 LVDs reduction (P = 0.020).
9
As shown in Table 9 , participants carrying GG genotype have the lowest MACE 10 incidence (P< 0.05) comparing with other genotypes. 1-year MACE incidence among 11 G allele carriers was 9.7%, significantly lower than that among CC genotype (P = 12 0.006). 
Discussion
14 Sympathetic-adrenergic system activation is one of the most important compensatory 15 mechanism of CHF which can ameliorative hemodynamic instability, by increasing 16 myocardial contractility and decreasing left ventricular diastolic pressure in the 17 early-phase(1). However, the long-lasting hyperactivation of sympathetic-adrenergic 18 system would induce cardiomyocytes apoptosis, accelerate cardiac remodeling, and 19 down-regulate β-receptor density(1). Substantial researches have demonstrated that β 20 blockers can reduce cardiovascular mortality, incidence of sudden cardiac death and 21 rehospitalization; therefore, the use of β blockers have been recommended as the 22 standard therapeutic medication in all CHF patients by most guidelines (7). 23 Previous researches demonstrated that gene polymorphisms involved in 24 catecholamine signaling might modulate CHF progression and patients'response to 25 therapy(2); however, the results are often controversial. So there are no definite 26 conclusions to guide clinic applications yet; also, most of these studies were 27 completed among Caucasians or Americans, but rarely Asians(6).
28
The two primary SNPs of ADRB1 gene are Ser49Gly and Arg389Gly gene 29 polymers. SNP of Arg389Gly in ADRB1 is in intracellular C-terminus, which is an (1) Lymperopoulos A, Rengo G, andKoch WJ. 
